Make Money Investing The Warren Buffett Way
Dividends are always great. They provide consistent income and can help improve the total return on an investment. The market is currently serving up some great dividend stocks in the healthcare industry. Each of these stocks have yields that are 4% or greater. That’s much better than the return that you will get on any savings account, certificate of deposit or treasury bond.
Access Pharmaceuticals (OTC: ACCP.OB, “Access”) develops and commercializes products for the treatment and supportive care of cancer patients, including:
- MuGard, an FDA-approved rinse for the management of patients with oral mucositis, a debilitating side effect of various cancer treatments
- ProLindac, now in Phase II clinical testing of patients with ovarian cancer
- The Cobalamin Platform, a drug delivery system for the oral administration of large molecules that are currently administered via injection (insulin, human growth hormone, fertility drugs, etc.)
MuGard has been commercially launched by Access’ partner, SpePharm, in six European countries, including the UK, Germany, Italy, Norway, Greece and Sweden. Over 15,000 bottles of MuGard have been used by over 2,000 patients to date. Access is now conducting pre-marketing activities, including ramping of commercial production, with the goal of a U.S. commercial launch by April 2010.
ProLindac is a next-generation DACH platinum anti-cancer compound which includes a proprietary nano-polymer drug delivery vehicle that allows for over ten-times the dose of platinum to be delivered in a targeted manner to cancer cells, with a much better safety profile compared to standard platinum-based drugs which cause significant and cumulative neurotoxicity.
Access will conduct a combination study evaluating ProLindac with Taxol (paclitaxel) for second-line treatment of platinum pre-treated patients with advanced ovarian cancer. This is a multi-center study being conducted in Europe in up to 25 patients with primary efficacy endpoint goal of achieving at least a 63% response rate. Access expects to begin patient dosing by April 2010.
The Cobalamin Platform is a drug delivery technology that involves coating a nano-particle with a vitamin B-12 analog (cobalamin) that binds to intrinsic factor in the gut and triggers binding to cellular receptors which absorb the entire package, resulting in exponential increases in absorption through the gut of large molecule drugs/hormones typically administered by injection.
In June 2009, Access announced that two bio-pharmaceutical companies would conduct preclinical, proof-of-concept studies in animals (rat and dog models of diabetes) before proceeding to more formal negotiations for the Company’s oral, long-acting (basal) insulin product candidate. Final results from the non-exclusive collaborators are possible during Q1 2010.
For more information on Access, visit the ProActive Capital Newsroom at www.proactivenewsroom.com.
This post was placed by IR GRO.
I have been looking for a solid pharmaceutical company to add to my stock portfolio. I had owned Pfizer previously but Pfizer appears to be a drug company with a dearth of drugs in its pipeline. The days of growth appear over and I am looking for a drug company with a brighter future. One of the stocks that has piqued my interest is Celgene (CELG). Celgene is a biotechnology company that discovers and produces therapies to treat cancer and other diseases. Celgene has a solid balance sheet and a promising pipeline of cancer drugs such as Vidaza, Revlimid and Thalomid. Celgene has virtually no debt and the company has over $5 per share in cash alone. The company has double digit profit margins and operating margins. Year over year earnings growth has been over 30%. My primary concerns are the astronomical P/E ratio and weakness in Q1 sales. Celgene currently has a P/E of 74. Analysts believe that the poor economy is to blame for lower Q1 sales and expect an increase due to a strengthening economy in Q3 and Q4. Celgene is still a little too expensive for me at its current price of $44. I don’t like a P/E ratio that is more then 2x the growth rate. If the stock were to weaken to the mid 30′s; I would see that as a great opportunity to pick up shares.
